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Abstract
Substantial experimental evidence suggests that several flavonoid classes are involved in glucose metabolism, but few
clinical or epidemiologic studies exist that provide supporting human evidence for this relationship. The objective of this
study was to determine if habitual intakes of specific flavonoid classes are related to incidence of type 2 diabetes (T2D).
We followed 2915 members of the Framingham Offspring cohort who were free of T2D at baseline from 1991 to 2008.
Diabetes was defined by either elevated fasting glucose ($7.0 mmol/L) or initiation of hypoglycemic medication during
follow-up. Dietary intakes of 6 flavonoid classes and total flavonoids were assessed using a validated, semiquantitative
food frequency questionnaire. We observed 308 incident cases of T2D during a mean follow-up period of 11.9 y (range
2.5–16.8 y). After multivariable adjusted, time-dependent analyses, which accounted for long-term flavonoid intake during
follow-up, each 2.5-fold increase in flavonol intake was associated with a 26% lower incidence of T2D [HR = 0.74 (95%CI:
0.61, 0.90); P-trend = 0.003] and each 2.5-fold increase in flavan-3-ol intake was marginally associated with an 11% lower
incidence of T2D [HR = 0.89 (95% CI: 0.80, 1.00); P-trend = 0.06]. No other associations between flavonoid classes and
risk of T2D were observed. Our observations support previous experimental evidence of a possible beneficial relationship
between increased flavonol intake and risk of T2D. J. Nutr. 143: 1474–1480, 2013.
Introduction
Type 2 diabetes (T2D) is a largely preventable condition with
serious health consequences, including a greater risk of heart
disease, stroke, peripheral neuropathy, renal disease, and vision
loss (1). Over the past 2 decades, the prevalence of T2D has
increased dramatically worldwide due largely to an increase in
obesity (2–7). Global estimates predict a continued growth in
worldwide diabetes prevalence for the foreseeable future (8).
It is well established that diet, even independent of body weight,
can influence the risk of T2D (9–11). Vegetables and fruits are notable
components of diets associated with lower risk of T2D (9–14). Plant
foods are not only good sources for nutrients associated with lower
T2D risk, such as fiber (15), potassium (16), andmagnesium (17), but
they also provide a large array of other bioactive compounds, such as
the polyphenols (18). These constitute the largest class of dietary
phytochemicals, with intakes of >1 g/d reported (19,20).
There is growing evidence based on in vitro and animal research
that polyphenols in general, and in particular the flavonoids, a class
of polyphenols, can improve glucose homeostasis and enhance
insulin secretion and sensitivity (21–25). Although there are relatively
few clinical studies that examined the effect of flavonoid interven-
tions in humans on glucose homeostasis and insulin resistance, a
recent systematic review of cocoa trials showed that cocoa/chocolate
interventions improved insulin resistance (HOMA-IR) due a signif-
icant reduction in insulin concentrations (26). To date, the limited
epidemiologic studies relating flavonoid intake toT2D risk have been
inconsistent (27–30). The lack of consistent findings may in part be
based on the use of incomplete flavonoid databases in earlier
epidemiologic studies (31) and the possibility that each flavonoid
classes may exert specific biological effects, resulting in distinct
impacts on health for the different classes (31,32).
The purpose of the present study was to examine in a well-
characterized, clinically examined population the hypothesis that
higher intakes of 3 flavonoid classes, specifically the flavonols,
flavan-3-ols, and anthocyanins, are associated with a lower
incidence of T2D whereas other flavonoid classes are not.
Subjects and Methods
Study design and population
The study participants were members of the Framingham Heart Study
Offspring cohort. The original Framingham Heart Study began in 1948
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with 5209 adults aged 28–62 y residing in Framingham, a town west of
Boston, Massachusetts (33) and has continued for more than 60 y, with
the survivors returning every 2 y for a physical examination and to
complete a series of questionnaires and laboratory and cardiovascular
tests. By 1971, the original cohort included 1644 husband-wife pairs and
378 individuals who had developed cardiovascular disease (CVD). The
offspring of these individuals and the offsprings spouses were invited to
form the Offspring cohort, and 5135 of the 6838 eligible individuals
participated in the first Framingham Offspring Study examination (34).
The Offspring cohort undergoes repeat examination approximately
every 3–4 y. For the present study, we used data derived from the 5th,
6th, 7th, and 8th study examinations, which spanned 17 y (1991–2008).
The 5th examination served as the baseline for these analyses.
This study was conducted according to the guidelines laid down in
the Declaration of Helsinki. All procedures involving human partici-
pants were approved by the Boston University Medical Center Institu-
tional Review Board and the present ancillary study was approved by the
Tufts Medical Center Institutional Review Board.
Measurements
Assessment of flavonoid intakes. Dietary intakes were assessed using
the Harvard semiquantitative FFQ (35) at the 5th, 6th, and 7th ex-
aminations. The FFQ consists of a list of foods with a standard serving
size and a selection of 9 frequency categories ranging from never or <1
serving/mo to $6 servings/d. Participants were asked to report their
frequency of consumption of each food item during the past year. Dietary
information was judged as unreliable and excluded from further study if
reported energy intakes were <600 kcal/d or >4000 kcal/d for women
and >4200 kcal/d for men or if >12 food items were left blank.
The flavonoid database used for the FFQ was previously described
(36) and was primarily derived from the USDA flavonoid content of
foods and the proanthocyanidin databases (37,38). The same flavonoid
database was used for all study examinations. We used the flavonoid
classification of Cassidy et al. (36) (Table 1) to define 6 flavonoid classes.
Total flavonoids were defined as the sum of all 6 classes. We did not
evaluate isoflavone intakes, because habitual intakes are very low in the
U.S. diet (39–42).
The validity of flavonoid intake from the Harvard FFQ has not been
directly assessed, but the validity for the food intake based on a
comparison of the FFQ and two 7-d diet records collected during the
year time interval covered by the FFQ was previously published (43).
This validation demonstrated relatively high correlation coefficients
between intakes from the FFQ and diet records for the major dietary
sources of flavonoids in the Framingham Offspring cohort, including
apples/pears (0.70), bananas (0.95), oranges (0.76), orange juice (0.78),
strawberries (0.38), muffins (0.66), tea (0.77), and red wine (0.83). The
correlation for blueberries was not presented.
Assessment of incident diabetes. Presence of diabetes was based on
elevated fasting glucose concentrations and/or a medical and medication
use history obtained by a physician at each study examination. We
defined diabetes at the baseline examination as a fasting plasma glucose
concentration $7.0 mmol/L, a 2-h oral glucose tolerance test glucose
concentration $11.1 mmol/L, or current use of hypoglycemic drug
therapy. For T2D incidence, participants were followed from baseline
through the 8th study examination (2005–2008). We used the examination
visit date on which a new case of diabetes was identified as the date of
diagnosis. We defined diabetes at follow-up as development of a fasting
plasma glucose concentration $7.0 mmol/L or new use of hypogly-
cemic drug therapy during the study interval.More than 99% of diabetes
cases among Framingham Offspring cohort are T2D (44). Diabetes
incidence was determined without knowledge of flavonoid intake or any
other dietary information.
Assessment of covariates. Covariates used in our analyses included
age at the 5th study examination, BMI, waist circumference, physical
activity, current smoking (y/n), prevalent CVD (y/n), and intakes of
energy, dietary fiber, potassium, magnesium, meat and processed meat,
and fruits and vegetables. The criteria for the diagnoses of cardiovascular
events have been described elsewhere (45). BMI was calculated as body
weight in kilograms divided by the square of height in meters using
examiner-assessed weight and height.Waist circumference was measured
to the nearest 0.25 inch (0.635 cm) at the level of the umbilicus. Physical
activity level was assessed using a physical activity index based on time
spent performing the activity in a typical day and the intensity of the
activity (46). We considered not only fruit and vegetable intake but also
some of the potentially bioactive compounds of fruit and vegetables,
including dietary fiber, potassium, and magnesium, which are related to
T2D incidence (15–17) as potential confounders. We also adjusted for
meat and processed meat, which have been suggested in some studies as
increasing T2D risk (47–50). Meat included chicken, turkey, hamburger,
liver, and beef, pork, or lamb as a mixed or main dish. Processed meat
included hot dogs, bacon, sausage, salami, and other processed meats.
Statistical methods
We used a time-dependent approach to the statistical analyses in which
flavonoid intake data were updated at each exam as the mean of intakes
from all previous exams. For example, events at the 6th examination
were related to intake at the 5th examination, events at the 7th exami-
nation were related to the mean of the intakes from the 5th and 6th
examinations, and events at the 8th examination were related to the
mean of the intakes from the 5th, 6th, and 7th examinations. If partici-
pants were missing intake data at one of the follow-up examinations, the
mean intake was based on the available intake data. Those who had data
missing at baseline or 2 consecutive follow-up examinations prior to the
development of T2D or the end of follow-up were excluded from anal-
yses. The natural logarithms of the different flavonoid class intakes were
used as the exposure variables. Our outcome was incident T2D. The
time-dependent covariates (BMI, smoking, and prevalent CVD) were
updated at each examination and all dietary covariates, like the flavo-
noid intakes, were updated as a cumulative mean.
HRs derived from Cox proportional hazards regression models (SAS
PROC PHREG) were used to characterize the prospective associations
between flavonoid intakes and incidence of T2D. Because flavonoid
intakes were transformed using a natural logarithm, the HRs represent
the risk for a relative difference in flavonoid intake. We presented HRs
for a 2.5-fold difference in flavonoid intake, which approximated the
smallest relative difference between the 75th and 25th percentile values
for intake of the individual flavonoid classes across study examinations
(Table 2).
We considered 3 different models based on inclusion of covariates,
each adding covariates to the prior model: 1) an age- and sex-adjusted
TABLE 1 Classification of flavonoids
Flavonoid class Flavonoid compounds
Flavonols Quercetin, kaempferol, myricetin, isohamnetin
Flavones Luteolin, apigenin
Flavanones Eriodictyol, hesperetin, naringenin
Flavan-3-ols Catechin, gallocatechin, epicatechin, epigallocatechin, epicatechin
3-gallate, epigallocatchin 3-gallate
Anthocyanins Cyanidin, delphinidin, malvidin, pelargonidin, petunidin, peonidin
Polymeric flavonoids Proanthocyanidins (dimers, trimers, 4–6 mers, 7–10 mers, polymers,
excluding monomers), theaflavins, thearubigins
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model (model 1); 2) model 1 with additional adjustment for BMI and
energy intake, prevalence of CVD, current smoking (model 2); and 3)
model 2 with additional adjustment for fruit and vegetable intake (model
3). Secondary analyses included mutual adjustment of the intakes from
the different flavonoid classes. Additional secondary analyses included
adjustment for dietary factors previously demonstrated to be associated
with T2D risk and potentially correlated with flavonoid intake, in-
cluding potassium, magnesium, fiber, and meat and processed meat, and
waist circumference and physical activity.
To examine the relation between the top food sources of the fla-
vonoids and T2D risk, we identified all foods that contributed at least
10% of the intake of each flavonoid classes for one or more of the study
examinations and related servings of these foods to T2D incidence. We
classified food intake into 4 categories (<1 serving/wk, 1–4 servings/wk,
5–6 servings/wk, and $7 servings/wk) and applied the same time-
dependent analysis approach using Cox proportional hazards regres-
sion that was described above for the flavonoids. A test for trend
across food serving categories was based on assigning the median
servings in each category to individuals in that category and treating
that resulting variable as a continuous variable in the regression
models.
All analyses were performed using SAS version 9.2 (SAS Institute).
P < 0.05 was considered significant.
Results
Of the 3799 Offspring cohort members who attended the 5th
examination, baseline for the present analysis, 346 individuals who
had diabetes were excluded. In addition, participants who were
missing data on diet (n = 333) or age, BMI, or smoking status (n =
16) at the 5th study examination and participants whoweremissing
dietary data at baseline or 2 consecutive follow-up examinations
prior to diagnosis of T2D or the end of follow-up (n = 189) were
excluded. The time-dependent analysis using cumulative mean
flavonoid intake was based on 2915 participants with 308 events
during a mean follow-up period of 11.9 y (range 2.5–16.8 y).
Table 2 displays the median and 25th and 75th percentile
values for intake of the different flavonoid classes (mg/d). Total
flavonoid intakes increased modestly over time, driven largely by
increased intakes of anthocyanins and polymeric flavonoids.
There was a wide range of intakes for all flavonoid classes. This
can be seen using the ratio of the 75th and 25th percentile values
for the different flavonoid classes. This ratio ranged from 2.3-
fold for flavonol intake at the 7th examination to 5.8-fold for
flavanone intake at the 5th examination. These data indicate that
the flavonoid intakes for the quarter of the population with the
highest intakes exceeded the intake of those in the lowest quarter
of the population by at least 2.3-fold for all flavonoid classes.
The mean age at baseline was 54 y old and participants were
on average overweight (Table 3). Men constituted 46% of the
sample, 19% of the sample were current smokers, and ~7% had
existing CVD. There were strong associations between many of
participants characteristics and lifestyle behaviors and total
flavonoid intakes. Men were much less likely to consume higher
amounts of total flavonoid than were women (P-trend < 0.001).
There was a modest increase in intakes with age (P-trend = 0.05)
and a decrease in intakes with increasing BMI (P-trend < 0.001).
Participants who were smokers and who had CVD were less
likely to have higher flavonoid intakes (P-trend < 0.001 and
0.005, respectively). Energy, fruit, vegetable, fiber, potassium,
and magnesium intakes were positively associated with flavo-
noid intakes (P-trend < 0.001), whereas meat and processed
TABLE 2 Flavonoid intake for members of the Framingham
Heart Study Offspring cohort at 5th through 7th examinations1
Flavonoid
class
Exam 5
(1991–1995)
Exam 6
(1995–1998)
Exam 7
(1998–2001)
mg/d mg/d mg/d
Flavonols 10.6 (6.6,16.4) 10.9 (6.9, 16.5) 10.9 (7.1, 16.5)
Flavones 1.6 (0.8, 2.5) 1.8 (0.9, 2.7) 2.0 (0.9, 2.8)
Flavanones 33.8 (10.5, 61.0) 38.9 (11.8, 62.6) 38.3 (11.6, 62.2)
Flavan-3-ols 21.8 (11.8, 49.4) 22.5 (12.3, 49.3) 23.4 (12.6, 51.5)
Anthocyanins 9.0 (3.4, 17.2) 10.1 (3.6, 18.1) 12.4 (3.9, 20.0)
Polymeric flavonoids 114 (60, 222) 116 (62, 225) 123 (64, 238)
Total flavonoids2 210 (124, 368) 214 (132, 379) 225 (136, 386)
1 Values are medians (25th, 75th percentiles), n = 2915.
2 Total flavonoid intakes exclude isoflavones, which were not measured in this study.
TABLE 3 Participant characteristics of members of the Framingham Heart Study Offspring cohort across quartile categories of total
flavonoid intake at baseline (5th examination)1
All (n = 2915) Q1 (n = 728) Q2 (n = 729) Q3 (n = 729) Q4 (n = 729) P-trend
Total flavonoid intake,2 mg/d 210 (2, 1963) 85 (2, 124) 165 (125, 210) 272 (211, 368) 537 (369, 1963)
Male,3 % 45.5 (43.7, 47.3) 51.0 (47.4, 54.6) 49.8 (46.2, 53.4) 48.0 (44.4, 51.6) 33.3 (29.7, 36.9) ,0.001
Age, y 54.2 (53.8, 54.5) 53.4 (52.7, 54.1) 54.2 (53.5, 54.9) 54.6 (53.9, 55.3) 54.6 (53.9, 55.3) 0.05
BMI,4 kg/m2 26.7 (26.5, 26.9) 27.2 (26.9, 27.5) 26.9 (26.6, 27.2) 26.6 (26.3, 26.9) 26.1 (25.8, 26.4) ,0.001
Current smoker, % 18.7 (17.3, 20.1) 30.0 (27.2, 32.8) 17.7 (14.9, 20.4) 14.7 (11.9, 17.4) 12.3 (9.5, 15.1) ,0.001
CVD, % 7.2 (6.3, 8.1) 9.1 (7.3, 10.9) 6.6 (4.8, 8.5) 8.0 (6.2, 9.9) 4.9 (3.1, 6.8) 0.005
Energy intake,4 MJ/d 7.46 (7.38, 7.56) 6.12 (5.99, 6.26) 7.39 (7.23, 7.55) 8.05 (7.87, 8.23) 8.53 (8.34, 8.72) ,0.001
Fiber,5 g/d 16.4 (16.2, 16.6) 13.5 (13.2, 13.8) 16.1 (15.8, 16.5) 18.0 (17.6, 18.4) 18.3 (17.9, 18.7) ,0.001
Potassium,5 g/d 2.88 (2.85, 2.90) 2.59 (2.55, 2.63) 2.82 (2.78, 2.87) 3.05 (3.00, 3.10) 3.07 (3.03, 3.11) ,0.001
Magnesium,5 mg/d 283 (281, 286) 258 (253, 263) 280 (275, 285) 298 (293, 303) 298 (293, 304) ,0.001
Vegetables,5 g/d 237 (233, 241) 206 (198, 213) 233 (225, 241) 255 (246, 264) 258 (249, 268) ,0.001
Fruits,5 g/d 201 (193, 209) 91 (84, 98) 220 (204, 237) 292 (271, 315) 278 (257, 300) ,0.001
Meat,5 g/d 88.3 (86.1, 90.5) 92.9 (88.2, 97.8) 91.5 (87.1, 96.1) 85.3 (81.2, 89.6) 83.8 (79.7, 88.2) 0.004
Processed meat,5 g/d 3.1 (2.9, 3.3) 4.5 (4.0, 5.1) 3.1 (2.7, 3.5) 2.9 (2.5, 3.3) 2.3 (2.0, 2.6) ,0.001
Cumulative diabetes incidence, % 10.7 (9.6–11.9) 13.1 (10.9–15.4) 10.7 (8.5–12.9) 9.6 (7.4–11.8) 9.4 (7.2–11.7) 0.08
1 CVD, cardiovascular disease.
2 Total flavonoid intakes exclude isoflavones, which were not measured in this study. Values are medians (min, max).
3 Values are age- and sex-adjusted means or percents (95% CIs). Percent male was only adjusted for age and age was only adjusted for sex.
4 Values are age- and sex-adjusted geometric means (95% CIs).
5 Values are age-, sex-, and energy-adjusted geometric means (95% CIs).
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meat intakes were inversely associated with flavonoid intakes
(P-trend = 0.004 and < 0.001, respectively). Age- and sex-adjusted
total flavonoid intake, based on only baseline values, was inversely
associated with cumulative incidence of T2D (P-trend = 0.08).
In multivariable-adjusted analyses, we observed a significant
inverse association between flavonol intakes and T2D incidence
(Table 4). These time-dependent analyses, which accounted for
long-term flavonoid intake during the follow-up period, dem-
onstrated that a 2.5-fold higher intake of flavonols was association
with a 26% lower incidence of T2D [HR = 0.74 (95% CI: 0.61,
0.90); P-trend = 0.003]. We also observed a marginally significant
inverse association between flavan-3-ol intake and T2D risk
after multivariable adjustment [HR = 0.89 (95%CI: 0.80, 1.00);
P-trend = 0.06). No other associations between intakes of other
flavonoid classes or total flavonoids and risk of T2D were
observed after multivariable adjustment. Further adjustment for
fruit and vegetable intakes resulted in a slightly stronger associ-
ation between flavonols and T2D incidence [HR = 0.68 (95% CI:
0.54, 0.86); P-trend = 0.001] but did not materially alter any of the
relationships between other flavonoids and T2D risk.
In secondary analyses, we adjusted the flavonol intakes for
intakes of all the other flavonoid classes and total flavonoids.
The relation between flavonol intake and T2D incidence was
unchanged by this adjustment, but the associations with flavan-
3-ols, polymeric flavonoids, and total flavonoids were all
attenuated after they were adjusted for flavonol intake. We
also adjusted for dietary fiber, potassium, magnesium, meat and
processed meat intakes, which had no effect on the association
between flavonol intake and T2D risk. Similarly, further
adjustment for dietary fiber and potassium did not affect the
observed association between flavan-3-ol intake and T2D, but
adjustment for meat and processed meat [HR = 0.91 (95% CI:
0.81, 1.02); P-trend = 0.11] and magnesium [HR = 0.92 (95%
CI: 0.82, 1.03); P-trend = 0.15] intakes did attenuate this
association. Finally, additional adjustment for waist circumfer-
ence and physical activity did not materially affect our findings.
We identified the foods that were the top contributors to each
of the flavonoid classes (Table 5). Based on the observed associ-
ations between flavonols and flavan-3-ols, we examined the
associations between the foods that were the major contributors
of these flavonoid classes and T2D incidence. Tea and apples/pears,
the only foods contributing $10% of the total flavonol intake,
together contributed ~30% of the flavonol intake. Tea, apples/
pears, and bananas, the 3 foods that contributed$10% of the total
flavan-3-ol intake, combined accounted for just more than 50% of
flavan-3-ol intake in this population. None of these foods was
individually associated with T2D risk (Table 6).
Discussion
In our study of a well-characterized population based on clinical
examinations, we observed that higher flavonol intakes were
associated with a 26% lower incidence of T2D. We also
observed a marginally significant inverse association between
flavan-3-ol intakes and risk of T2D, but there was no association
with anthocyanin intake. None of the individual foods that were
major contributors of the flavonols and flavan-3-ols were
individually associated with T2D incidence. This latter obser-
vation suggests that the observed associations between the
flavonols and flavan-3-ols were not a consequence of confound-
ing by higher consumption foods that happen to be high in these
flavonoids.
Results from 2 previous observational studies also suggested
an inverse association between habitual flavonol intake and T2D
risk. Wedick et al. (29) observed a significant inverse association
between flavonol intake and T2D incidence in the Nurses
Health Study cohort (16% reduction in risk) and the Health
Professionals Follow-up Study cohort (12% reduction in risk),
but not in a cohort of younger women (Nurses Health Study II)
or in a pooled analyses of their 3 cohorts. Knekt et al. (27)
showed a marginally significant inverse association between
intakes of the flavonols quercetin and myricetin, but not
kaempferol, and incidence of T2D in Finnish men and women.
Earlier epidemiological studies by Nettleton et al. (28) and Song
et al. (30) reported no associations between any flavonoid class
and T2D risk in U.S. women, but these studies were performed
before a more complete version of the flavonoid database was
available. Our observation that flavonol intake was associated
with a lower risk of T2D is supported by animal studies, which
showed that the flavonol quercetin decreased plasma glucose
concentrations, improved insulin concentrations, preserved the
integrity of pancreatic B-cells, alleviated diabetic symptoms, and
reduced hepatic gene expression in streptozotocin-induced
diabetic models (21,51–53).
There is limited epidemiologic evidence supporting a rela-
tionship between flavan-3-ol intake and T2D risk. Wedick et al.
TABLE 4 Relation between cumulative mean flavonoid intake and diabetes incidence in members of the
Framingham Heart Study Offspring cohort: time-dependent analyses1
Flavonoid class
Age and sex adjusted Multivariable model2
Multivariable model
plus vegetable and fruit intake
HR (CI) P value HR (CI) P value HR (CI) P value
Flavonols 0.72 (0.60–0.87) ,0.001 0.74 (0.61–0.90) 0.003 0.68 (0.54, 0.86) 0.001
Flavones 0.90 (0.75–1.09) 0.29 0.93 (0.77–1.14) 0.50 0.99 (0.77, 1.28) 0.97
Flavanones 0.97 (0.89–1.06) 0.52 0.97 (0.89–1.07) 0.58 1.01 (0.90, 1.13) 0.86
Flavan-3-ols 0.86 (0.77–0.96) 0.006 0.89 (0.80–1.00) 0.06 0.90 (0.80, 1.01) 0.07
Anthocyanins 0.98 (0.88–1.09) 0.65 0.98 (0.88–1.10) 0.78 1.00 (0.88, 1.13) 0.98
Polymeric flavonoids 0.88 (0.78–0.99) 0.03 0.90 (0.79–1.02) 0.11 0.90 (0.79, 1.04) 0.15
Total flavonoids3 0.85 (0.74–0.98) 0.03 0.88 (0.76–1.02) 0.10 0.89 (0.75, 1.05) 0.17
1 Flavonoid intakes were transformed using natural logarithms. HRs represent the difference in risk associated with a 2.5-fold increase in
flavonoid intake.
2 Multivariable model is adjusted for sex and time dependent variables age, cardiovascular disease (y/n), current smoker (y/n), BMI, and
cumulative mean energy intake.
3 Total flavonoid intakes exclude isoflavones, which were not measured in this study.
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(29) observed an inverse association between flavan-3-ol intake
and T2D risk in older women (Nurses Health Study) but not in
their other 2 cohorts. Two early publications that did not have
access to the more complete version of the flavonoid database
reported no associations between habitual flavan-3-ol intakes
and risk of T2D (28,30). Our observation that flavan-3-ol intake
was associated with a lower risk of T2D is supported by consistent
findings for both acute and chronic effects observed in dietary
intervention trials of flavan-3-ol–rich products. To date, these trials
have mainly focused on cocoa/chocolate and cardiovascular health
biomarkers. In a systematic review of 42 acute and short-term
chronic trials (duration #18 wk), insulin resistance as assessed by
HOMA-IR was improved by chocolate/cocoa as a result of a sig-
nificant reduction in serum insulin concentrations (26). A combined
flavan-3-ol and isoflavone 1-y intervention trial in medicated T2D
postmenopausal women also demonstrated a significant improve-
ment in insulin resistance and sensitivity (54). The available data
also suggest that dose of the flavan-3-ol epicatechin may be
important for cardiovascular risk, with doses >50 mg being
more efficacious; however, too few studies were available to
assess the effect of dose on HOMA-IR and insulin (26). The
mean intake in our study increased from 21.8 to 23.4 mg/d
across follow-up, with ~25% or more of the study population
achieving intakes of 50 mg/d.
In our study, we did not confirm the protective association for
anthocyanin intake observed by Wedick et al. (29). This was
surprising given the growing mechanistic data showing that
anthocyanins and their degradation products/metabolites en-
hance insulin sensitivity and secretion, protect b-cell function,
and improve glucose homeostasis (23,55,56). We considered the
possibility that apparent differences in dietary sources and
amounts of anthocyanins might explain the discrepancy between
our findings and those of Wedick et al., but our analyses did not
support either explanation.
The major strengths of our study were the large sample size,
availability of meticulous clinical examinations, the use of
multiple dietary assessment measures of flavonoid intake so that
we could assess cumulative intakes, and the availability of a
more complete flavonoid database to more accurately charac-
terize the intake of the range of flavonoid classes present in the
habitual diet. In addition to these strengths, there are some
potential limitations. The importance of vegetables and fruits as
sources of many flavonoid classes confound our ability to
separate the independent contributions of overall vegetable and
fruit intake and intakes of the flavonoids. However, adjustment
for some of the potentially bioactive components of the fruits
and vegetables associated with T2D risk, including fiber (15),
potassium (16), and magnesium (17), had no impact on the
flavonol intake association, suggesting that this association was
independent of these and perhaps other phytochemical compo-
nents of vegetables and fruits. However, the relation between
flavan-3-ols and T2D risk was slightly attenuated by this
adjustment. Our findings are based on observational data and
we cannot rule out the potential for residual bias related to
lifestyle differences between individuals consuming higher or
lower amounts of flavonoids. Finally, our findings were based on
a cohort that was largely Caucasian of western European
heritage, so generalizability to other race and ethnic groups may
be limited.
TABLE 5 Mean contributions of flavonoids from foods provid-
ing at least 10% of the total intake for each flavonoid class at one
or more examination cycles for members of the Framingham
Heart Study Offspring cohort
Flavonoid class contribution
Exam 5 Exam 6 Exam 7
%
Flavonols
Tea 17.5 17.6 17.5
Apples/pears 13.1 12.3 12.0
Flavones
Orange juice 39.0 38.9 39.7
Oranges 12.5 12.9 11.3
Red wine 8.0 9.8 10.8
Flavanones
Orange juice 50.1 50.1 52.6
Oranges 22.4 23.2 21.4
Flavan-3-ols
Tea 30.7 31.3 31.5
Apples/pears 12.6 11.5 11.1
Bananas 10.3 11.2 11.4
Anthocyanins
Muffins 21.9 18.8 16.7
Blueberries 20.1 21.5 24.9
Strawberries 14.7 14.4 14.9
Apples/pears 13.7 12.2 11.0
Red wine 9.7 12.1 13.1
Polymeric flavonoids
Tea 25.7 26.2 26.0
Apples/pears 25.1 23.5 22.7
Total flavonoids
Tea 22.2 22.2 22.2
Apples/pears 16.3 15.2 14.5
Orange juice 12.5 12.8 13.2
TABLE 6 Relation between cumulative mean food intake and
diabetes incidence in members of the Framingham Heart Study
Offspring cohort: time-dependent analyses
Food1
Age and sex adjusted Multivariable adjusted2
HR (95% CI) P value HR (95% CI) P value
Tea, mL/wk
,30 1.0 —3 1.0 —
30–132 0.89 (0.69–1.15) 0.38 0.95 (0.74–1.22) 0.68
133–191 0.99 (0.57–1.72) 0.97 0.99 (0.57–1.73) 0.98
$192 0.86 (0.60–1.22) 0.39 0.97 (0.68–1.39) 0.88
P-trend 0.42 0.89
Apples and pears, g/wk
,138 1.0 — 1.0 —
138–620 1.13 (0.76–1.66) 0.55 0.99 (0.67–1.46) 0.96
621–896 0.67 (0.34–1.35) 0.27 0.63 (0.31–1.26) 0.19
$897 0.76 (0.36–1.61) 0.47 0.73 (0.35–1.56) 0.42
P-trend 0.20 0.18
Banana, g/wk
,114 1.0 — 1.0 —
114–512 1.27 (0.85–1.89) 0.25 1.16 (0.78–1.73) 0.47
513–740 1.07 (0.60–1.89) 0.83 1.06 (0.59–1.89) 0.84
$741 1.29 (0.72–2.29) 0.39 1.36 (0.76–2.43) 0.30
P-trend 0.72 0.43
1 Foods contributing at least 10% of the total intake for flavonols and flavan-3-ols.
2 Multivariable models are adjusted for sex and time-dependent variables age, cardiovas-
cular disease (y/n), current smoker (y/n), BMI, and cumulative mean energy intake.
3 Referent category.
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In summary, the evidence relating flavonoid class intake to
risk of T2D is promising although still very limited. To date, we
are not aware of any human intervention studies relating
flavonoid intake to T2D incidence, and there are few long-
term clinical studies that have examined interventions with
flavonoid-rich diets in humans with respect to intermediate risk
factors for T2D such as glucose homeostasis and insulin
resistance. Our knowledge of the effects of flavonoids on T2D
risk would greatly benefit from additional human intervention
studies and prospective observational studies examining rela-
tions with markers of T2D risk.
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